亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

The efficacy and safety of anlotinib in neoadjuvant treatment in locally advanced thyroid cancer: A single-arm phase II clinical trial.

作者
Naisi Huang,Guohua Sun,Yulong Wang,Jiaying Chen,Qing Guan,Zhong‐Wu Lu,Jun Xiang,Wenjun Wei,Ben Ma,Qinghai Ji,Yu Wang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): 6069-6069 被引量:9
标识
DOI:10.1200/jco.2021.39.15_suppl.6069
摘要

6069 Background: Surgery is the primary treatment for locally advanced thyroid cancer (TC). For some locally advanced TC, R0/R1 resection could not be achieved at initial diagnosis and neoadjuvant treatment would be an option. However, there is still little evidence regarding neoadjuvant treatment in locally advanced TC. Methods: This single-arm, phase 2 study investigated the efficacy and safety of Anlotinib (12mg orally daily, for two weeks on/on week off) for 2-6 cycles in patients with locally advanced TC in the neoadjuvant setting. Operable patients received surgery after neoadjuvant treatment. The primary endpoint was objective response rate (ORR). Results: A total of 13 patients were included and received an average of 3.5 cycles (range: 3-6 cycles) of Anlotinib treatment. 12 cases were papillary thyroid cancer, and 1 was follicular thyroid cancer. The ORR of Anlotinib was 76.9% with 10 partial response (PR), 2 stable disease (SD), and 1 progressive disease (PD). 8 PR and 1 SD patients received surgery after neoadjuvant treatment, of whom 8 had R0/1 resections and 1 had R2 resection. 2 PR patients refused to have surgery and the rest 2 patients were not operable. The R0/1 resection rate for intent to treat population was 61.5% and for per-protocol population was 72.7%. The maximum reduction in sum of tumor diameter was an average of 34.8% (range: 30.9%-45.5%) for PR patients. Most adverse events were grade 1 or 2. Common adverse events of all grade were hypertension (76.9%), hypertriglyceridemia (69.2%), proteinuria (53.8%), TSH increase (53.8%), cholesterol elevation (53.8%) and hand-foot syndrome (38.5%). The majority of adverse events discontinued after the neoadjuvant treatment stopped. Conclusions: Anlotinib demonstrated antitumor activity in the neoadjuvant treatment in locally advanced TC and the majority of patients achieved R0/1 resection. Adverse events were consistent with the known Anlotinib adverse event profile. These results suggest that Anlotinib neoadjuvant treatment represents a new option for locally advanced TC. Clinical trial information: NCT04309136.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JiaxinChen完成签到 ,获得积分10
1秒前
满意的楷瑞完成签到,获得积分10
2秒前
陆上飞完成签到,获得积分10
3秒前
4秒前
10秒前
游标卡尺发布了新的文献求助10
15秒前
含蓄的觅波完成签到,获得积分10
22秒前
彭于晏的应助被游标卡尺采纳,获得10
30秒前
Owen的应助被笑点低听枫采纳,获得10
37秒前
46秒前
个性鹭洋完成签到,获得积分10
55秒前
昌莆完成签到 ,获得积分10
1分钟前
1分钟前
安静的卿完成签到,获得积分10
1分钟前
滕皓轩完成签到 ,获得积分20
1分钟前
1分钟前
1分钟前
游标卡尺发布了新的文献求助10
1分钟前
顾矜的应助被游标卡尺采纳,获得10
1分钟前
呆萌保温杯完成签到,获得积分10
1分钟前
1分钟前
踏实的元蝶完成签到,获得积分10
1分钟前
Mario发布了新的文献求助10
1分钟前
1分钟前
英俊的铭的应助被ZZWZHENG采纳,获得50
2分钟前
Sunny完成签到,获得积分10
2分钟前
lzl008完成签到 ,获得积分0
2分钟前
2分钟前
Johnny19完成签到,获得积分10
2分钟前
lzl007完成签到 ,获得积分0
2分钟前
Maestro_S的应助被科研通管家采纳,获得10
2分钟前
2分钟前
幸福御姐完成签到,获得积分10
2分钟前
游标卡尺发布了新的文献求助10
2分钟前
2分钟前
儒雅的半青完成签到,获得积分10
2分钟前
FashionBoy的应助被游标卡尺采纳,获得10
2分钟前
3分钟前
激动的发卡完成签到,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179956
求助须知:如何正确求助?哪些是违规求助? 9570159
关于积分的说明 21808414
捐赠科研通 7775796
什么是DOI,文献DOI怎么找? 3433231
关于科研通互助平台的介绍 2557352
邀请新用户注册赠送积分活动 2478935